<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68827">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01926340</url>
  </required_header>
  <id_info>
    <org_study_id>RPS FU study</org_study_id>
    <nct_id>NCT01926340</nct_id>
  </id_info>
  <brief_title>Early Medication Discontinuation and Long-term Clinical Outcome in FEP</brief_title>
  <acronym>FEP</acronym>
  <official_title>The Impact of Early Medication Discontinuation on Long-term Clinical Outcome in First Episode Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <authority>Hong Kong: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to examine the relationship between early maintenance therapy decision in
      first episode psychosis and the subsequent long-term clinical outcome at 8-year by comparing
      a group of patients who were randomized to discontinue or continue mediation in the early
      stage of their psychotic disorders.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Recovery Status</measure>
    <time_frame>Baseline/cross-sectional study</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of patients having recovered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functioning status</measure>
    <time_frame>Baseline/ cross-sectional</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of patients having good functioning</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relapse</measure>
    <time_frame>Baseline/ cross-sectional</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of patients having relapsed</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Schizophrenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Psychiatric outpatient clinics in Hong Kong
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of schizophrenia or non-affective psychosis (schizophreniform disorder,
             schizoaffective disorder, brief psychotic disorder, or psychosis not otherwise
             specified) (DSM-IV)14,

          -  Aged 18 to 65 years,

          -  Had been treated with antipsychotic drugs for at least 12 months with good adherence
             to treatment

          -  No history of relapse or exacerbation or had to be asymptomatic at study entry.

        Exclusion Criteria:

          -  A diagnosis of drug-induced psychosis,

          -  Current treatment with clozapine, with mood stabilizing medications (lithium,
             valproate or carbamazepine) or with depot medication, or

          -  Had high risk of suicide or violence.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric YH Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 18, 2013</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
